On this page
Glycine
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Glycine | 1.5 g/100mL | 800401 | View |
Forms, strengths and routes
Source: NDC DirectoryRegulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 016784-001 | GLYCINE 1.5% IN PLASTIC CONTAINER | SOLUTION | GLYCINE | Prescription | AT |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 35 | Manufacturing (CMC) | Approved | September 12, 2014 | Standard |
| Supplement | 34 | Manufacturing (CMC) | Approved | May 8, 2013 | Standard |
| Supplement | 30 | Manufacturing (CMC) | Approved | July 8, 2002 | Standard |
| Supplement | 29 | Manufacturing (CMC) | Approved | April 3, 2002 | Standard |
| Supplement | 28 | Manufacturing (CMC) | Approved | April 12, 2000 | Standard |
| Supplement | 27 | Manufacturing (CMC) | Approved | March 25, 1998 | Standard |
| Supplement | 26 | Manufacturing (CMC) | Approved | May 21, 1997 | Standard |
| Supplement | 25 | Manufacturing (CMC) | Approved | January 13, 1995 | Standard |
| Supplement | 24 | Manufacturing (CMC) | Approved | September 11, 1990 | Standard |
| Supplement | 22 | Manufacturing (CMC) | Approved | April 19, 1988 | Standard |
| Supplement | 19 | Manufacturing (CMC) | Approved | March 5, 1987 | Standard |
| Supplement | 20 | Labeling | Approved | July 27, 1985 | — |
| Supplement | 16 | Manufacturing (CMC) | Approved | May 24, 1985 | Standard |
| Supplement | 17 | Manufacturing (CMC) | Approved | May 17, 1985 | Standard |
| Supplement | 18 | Manufacturing (CMC) | Approved | April 3, 1985 | Standard |
| Supplement | 15 | Labeling | Approved | February 18, 1983 | — |
| Supplement | 12 | Manufacturing (CMC) | Approved | November 6, 1981 | Standard |
| Supplement | 11 | Labeling | Approved | October 27, 1981 | — |
| Supplement | 10 | Manufacturing (CMC) | Approved | October 27, 1981 | Standard |
| Supplement | 13 | Manufacturing (CMC) | Approved | September 28, 1981 | Standard |
| Supplement | 14 | Manufacturing (CMC) | Approved | September 24, 1981 | Standard |
| Supplement | 9 | Manufacturing (CMC) | Approved | July 16, 1980 | Standard |
| Supplement | 8 | Manufacturing (CMC) | Approved | February 15, 1980 | Standard |
| Supplement | 7 | Labeling | Approved | September 25, 1979 | — |
| Supplement | 6 | Manufacturing (CMC) | Approved | September 24, 1979 | Standard |
| Supplement | 3 | Labeling | Approved | June 19, 1979 | — |
| Supplement | 4 | Manufacturing (CMC) | Approved | April 26, 1979 | Standard |
| Supplement | 5 | Labeling | Approved | April 12, 1979 | — |
| Supplement | 1 | Manufacturing (CMC) | Approved | October 30, 1978 | Standard |
| Supplement | 2 | Manufacturing (CMC) | Approved | August 28, 1978 | Standard |
| Original application | 1 | Type 5 - New Formulation or New Manufacturer | Approved | February 6, 1978 | Standard |
Review documents
- 0 · Supplement · September 19, 2014
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20251021). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE 1.5% Glycine Irrigation, USP is indicated for use as irrigating fluid during transurethral prostatic resection and other transurethral surgical procedures.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION 1.5% Glycine Irrigation, USP should be administered only by transurethral instillation with appropriate urologic instrumentation. A disposable irrigation set should be used. The total volume of solution used for irrigation is solely at the discretion of the surgeon. Height of container(s) above the operating table in excess of 60 cm (approx. 2 ft.) has been reported to increase intravascular absorption of the irrigating fluid. Drug Interactions Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution container permits. See PRECAUTIONS.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS 1.5% Glycine Irrigation USP is not for injection. It is contraindicated in patients with anuria.
Warnings
openFDA Drug LabelingWARNINGS Solutions for urologic irrigation must be used with caution in patients with severe cardiopulmonary or renal dysfunction. The amount of fluid absorbed during a transurethral resection is a function of the volume and hydrostatic pressure of the irrigant used, the number and size of venous sinuses opened, and the duration of the procedure. Since irrigating fluids used during transurethral prostatectomy have been demonstrated to enter the systemic circulation in relatively large volumes, any irrigation solution must be regarded as a systemic drug. Absorption of large amounts of fluids containing glycine and the resultant osmotic diuresis may significantly affect cardiopulmonary and renal dynamics. Absorption of large amounts of irrigating solution can also result in pronounced hyponatremia and water intoxication. After opening container, the contents should be used promptly to minimize the possibility of bacterial growth or pyrogen formation. Discard unused portion of irrigating solution since it contains no preservative.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS Adverse reactions may result from intravascular absorption of glycine. Large intravenous doses of glycine are known to cause salivation, nausea and lightheadedness. Other consequences of absorption of urologic irrigating solutions include fluid and electrolyte disturbances such as acidosis, electrolyte loss, marked diuresis, urinary retention, edema, dryness of mouth, thirst, dehydration, coma from hyponatremia, secondary hyponatremia due to fluid overload, and hyperammonemia with resultant coma and/or encephalopathy; cardiovascular disorders such as hypotension, tachycardia, angina-like pains; pulmonary disorders such as pulmonary congestion; and other general reactions such as blurred vision, convulsions, nausea, vomiting, rhinitis, chills, vertigo, backache, transient blindness and urticaria. Allergic reactions from glycine are unknown or exceedingly rare. Should any adverse reaction occur, discontinue the irrigant, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.
Description
openFDA Drug LabelingDESCRIPTION 1.5% Glycine Irrigation, USP is a sterile, nonpyrogenic, hypotonic, aqueous solution of glycine intended only for urologic irrigation during transurethral surgical procedures. Each 100 mL contains 1.5 g of glycine in water for injection. The solution is nonelectrolytic, hypotonic and has an osmolarity of 200 mOsmol/liter (calc.); pH 6.0 (4.5 to 6.5). The solution contains no bacteriostat, antimicrobial agent or added buffer and is intended only for use as a single-dose irrigation. When smaller volumes are required, the unused portion should be discarded. 1.5% Glycine Irrigation is a urologic nonelectrolyte irrigant. Glycine, USP is chemically designated aminoacetic acid (C 2 H 5 NO 2 ), a white crystalline powder freely soluble in water. It has the following structural formula: NH 2 CH 2 COOH Water for Injection, USP is chemically designated H 2 0. The flexible plastic container is fabricated from a specially formulated polyvinylchloride. Water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly. The semi-rigid container is fabricated from a specially formulated polyolefin. It is a copolymer of ethylene and propylene. The container requires no vapor barrier to maintain the proper drug concentration. The flexible plastic container is fabricated from a specially formulated polyvinylchloride. Water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly. Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials. Exposure to temperatures above 25°C/77°F during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period.
Overdosage
openFDA Drug LabelingOVERDOSAGE In the event of overhydration or solute overload, re-evaluate the patient and institute appropriate corrective measures. See WARNINGS, PRECAUTIONS and ADVERSE REACTIONS.
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED 1.5% Glycine Irrigation, USP is supplied in single-dose 3000 mL flexible irrigation container NDC No. Product Container Size (mL) 0409-7974-08 1.5% Glycine Irrigation, USP 3000 mL 0990-7974-08 1.5% Glycine Irrigation, USP 3000 mL ICU Medical is transitioning NDC codes from the "0409" to a "0990" labeler code. Both NDC codes are expected to be in the market for a period of time. Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing. Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Revised: November, 2022 ICU Medical, Inc., Lake Forest, Illinois, 60045, USA IFU0000478
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: GLYCINE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 0264-7390-60 | 0264-7390 | B. Braun Medical Inc. | 4 CONTAINER in 1 CASE (0264-7390-60) / 3000 mL in 1 CONTAINER | December 4, 2013 |
| 0990-7974-08 | 0990-7974 | ICU Medical Inc. | 4 POUCH in 1 CASE (0990-7974-08) / 1 BAG in 1 POUCH / 3000 mL in 1 BAG | July 1, 2019 |
| 0264-7390 | 0264-7390 | B. Braun Medical Inc. | — | December 4, 2013 |
| 0990-7974 | 0990-7974 | ICU Medical Inc. | — | July 1, 2019 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 10 sections on this page.